Stockreport

Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today [Read more]